お知らせ

2017/11/21

ダラツムマブを多発性骨髄腫患者に対する一次療法とする適応症拡大を申請

Janssen Submits Application to U.S. FDA to Expand Indication for DARZALEX® (daratumumab) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma who are Transplant Ineligible
November 21, 2017
Janssen (J&J)Multiple myelomaHematologic cancer (market)CD38